Hera Biotech’s Post

The predictive and diagnostic tools created by Class 10 address some of the most prevalent problems for everyday patients. Today, we are excited to introduce Healthplus.ai and Hera Biotech. Healthplus.ai is enabling proactive surgery care through personalized complication predictions. Healthplus.ai's CE IIa certified solution, PERISCOPE®, is an AI-based decision support tool that highly-accurately predicts infection risks using existing EHR data, facilitating early intervention, eliminating unnecessary hospital stays, and reducing readmissions. Healthplus.ai uses real-time data along with validated & locally recalibrated machine learning algorithms to integrate with the existing workflow to aid clinical staff, delivering proactive and individualized care. Hera Biotech offers the world’s first non-surgical test for endometriosis, the number one cause of female infertility. Hera's test, MetriDx™, provides definitive diagnosis and staging of endometriosis through tissue-based analysis. MetriDx™ measures the expression patterns of an endometriosis-specific gene panel. Hera Biotech's patent-protected panel is heavily based on the expression profiles of a gene set implicated in a number of other invasive processes. Hera Biotech primarily serves the OB/GYN and fertility solutions markets with its innovative diagnostic tool. #CSaccelerator #healthinnovate #healthaccelerator #HIT #healthdisruptors #CSAclass10

An exciting case showcasing the importance of clinical manifestations, which is crucial for accurate imaging interpretation and patient management. Today a patient presented to the OPD with complaint of abdominal pain since two weeks. While taking the patient's history, I noticed his lower lip, which showed multiple small macules. Similar macules were also seen on the lower abdomen and dorsum of both the foot. Family history was also positive for GI malignancies. Colonoscopy showed multiple polyps in the descending colon. The biopsy was taken from a polyp and confirmed to be hamartomatous. The Peutz-Jeghers Syndrome is a rare autosomal dominant syndrome characterized by mucocutaneous pigmentations, multiple gastrointestinal hamartomatous polyps, and an elevated risk of malignancy. Most of the cases result from a mutation in the STK11 tumor suppressor gene. As a result, PJS is associated with an increased risk of malignancies resulting in significant morbidity and mortality. The mucocutaneus pigmentations seen in PJS are due to characteristic macules, typically seen on the mouth, buccal mucosa, and genital and perianal mucosal surfaces. Distinctive features of PJS include perioral pigmentations from perioral freckles with darker color, dense claustration, and crossing of the vermillion border. Note: A proper consent was taken from the patient for the clinical picture. #gastroenterology #peutzjegherssyndrome #PJS #geneticdisorder #raredisease #hamartomatouspolyps #gihealth #hereditarycondition #cancerrisk #medicalawareness #patientsupport #healthcare #genetictesting #colonhealth #intestinalpolyp

https://lnkd.in/dJ6SibHe Finally out our latest SRMA on Computer-aided diagnosis for leaving colorectal polyps in situ, published in the prestigious Annals Internal Medicine! * Ten studies, including 3620 patients * Pooled sensitivity with CADx alone 87.3% (95% CI, 79.2% to 92.5%) and specificity 88.9% (CI, 81.7% to 93.5%) in predicting neoplastic change. * No difference before vs after CAD in the proportion of polyps predicted to be nonneoplastic that would avoid removal (RR 1.06, CI, 0.96 to 1.17) nor in the proportion of neoplastic polyps that would be erroneously left in situ (RR, 0.95, 0.69 to 1.33). Therefore, CAD provided no incremental benefit or harm in the management of small rectosigmoid polyps during colonoscopy. Cesare Hassan, Masashi Misawa Tommy Rizkala Yuichi Mori Shahnaz Sultan Giulio Antonelli Marco Spadaccini Britt B S L Houwen Emanuele Rondonotti Harsh Patel Kareem Khalaf James Weiquan Li Gloria M Fernandez Pradeep Bhandari Evelien Dekker Seth Gross Tyler Berzin Per Olav Vandvik Loredana Correale Shin-Ei Kudo Prateek Sharma Douglas Rex Alessandro Repici Farid Foroutan

Adapted from the Article:Artificial intelligence in gastroenterology: A state-of-the-art review Artificial intelligence (AI) clinical applications in gastroenterology and hepatology, which heavily relies on imaging, have dramatically expanded in the last 20 years. These applications include the detection of lesions, identification of premalignant or malignant lesions, development of objective scoring systems for risk stratification, predicting disease prognosis or treatment response, or evaluation of metrics such as bowel preparation score or quality of endoscopic examination

Innovative and comprehensive Gastrointestinal AI tools to analyze your H&E stained tissue for UC, Crohn's and Celiac Disease. We can deploy these tools both in a retrospective and prospective manner.....

Curious about the tissue microenvironment in IBD? Discover AI-driven insights using IBD Explore™! Check out our demo to see how AI-powered digital pathology can enhance your IBD research. #IBD #PrecisionMedicine #AIpoweredPathology #PathAI

terrific discussion yesterday led by the ADEA oral diagnosis community [thanks Sahar Mirfarsi, DDS, FICD for organizing the virtual session] the discussion focused on challenges and opportunities incorporating orofacial pain into the #curriculum and addressing #accreditation standards; reflecting on the discussion, I see the topic as one of five pillars in practical #oralmedicine instruction: management of oral ulcerative, immune, and inflammatory disease the impact of systemic disease and the role of #medicine in oral health management soft and hard tissue #radiology and #pathology, biopsy and tissue submission, and communication with the laboratory oral oncology, tumor board, and post-surgical and post-oncologic care in #dentistry orofacial pain, musculoskeletal disorders, and the role of healthcare practitioners in diagnosis and referral

https://lnkd.in/gRxU3Wg6 Mr.Naresh Ahuja, Founder & CEO of SMS Scientific Products Pvt Ltd Spoke exclusively with Modern Medi Health, A Healthcare Media Network (Empowering Patient Education: SMS's Innovative Consultation Tool Transforms Doctor-Patient Communication) Imagine a scenario where a urologist is consulting with a patient about prostate health. Traditionally, explaining complex prostate conditions like benign prostatic hyperplasia (BPH) or prostate cancer relied heavily on verbal descriptions, anatomical models, and medical jargon. This often led to confusion and limited patient understanding.   With SMS's prostate consultation tool, the urologist now has access to a comprehensive set of illustration boards specifically designed for prostate health discussions. These boards feature detailed illustrations of the prostate gland, urinary tract, and common prostate conditions. For instance, one board depicts the normal anatomy of the prostate, highlighting key structures and functions. Naresh Ahuja SMS Scientific Products PVT.LTD

The role of accurate and reliable laboratory diagnostic technique is paramount for early and veracious detection of diseases. In our new piece of #published work, we investigated the #accuracy of disregulated long noncoding RNAs (#lncRNAs) and circular RNAs (#circRNAs) in diagnosing Inflammatory Bowel Diseases (#IBD) overcoming the nonspecific, conventional and invasive diagnosis techniques including clinical symptoms, radiology, endoscopy and repeated biopsy examinations. Accordingly, lncRNAs exhibit #high diagnostic accuracy (pooled #sensitivity 0.94 (95% CI: 0.87-0.97), #specificity 0.99 (95% CI: 0.89-1.00), and #AUC 0.99 (95% CI: 0.97-0.99) along with #PLR, #NLR, and #DOR values of 64.25 (95% CI: 7.39-558.66), 0.06 (95% CI: 0.03-0.13), and 1055.25 (95% CI: 70.61-15770.77), respectively) in distinguishing patients with IBD from healthy controls signifying their possible use as #potential #biomarkers, while circRNAs showed moderate diagnostic accuracy. Our investigation also point out the performance of serum #lncRNA H19 as a better and more suitable diagnostic marker for IBD with heightened ability for both #exclusion and #confirmation of #IBD. #Research, #New #Publication, #Laboratory diagnosis, #Diagnostic markers, #lncRNA, #circRNA, #IBD, #Meta-analysis

term male neonate with MAS,HIE,pulmonary hypertension,& Respiratory failure (OI 45) POCLUS diagnostic criteria for MAS(finding is heterogeneous bilateral lung pathology :- 1- Consolidation & airbronchogram 2-Abnormal pleural line 3-B line 4-Atelectasis 5-Pleural effusion 6-lung pulse Note from 1 to 4 present in All cases of MAS